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Abstract
AIM: To investigate the genetic background of human 
defensin expression in type 1 and 2 diabetes.
METHODS: Associations between DEFA1/DEFA3  gene 
copy number polymorphism and diabetes as well as 
between the promoter polymorphisms of DEFB1  and 
diabetes were studied. The copy number variation of 
the DEFA1/DEFA3  genes was determined in 257 dia-
betic patients (117 patients with type 1 and 140 with 
type 2 diabetes). The control group consisted of 221 
age- and gender-matched healthy blood donors. The 
cumulative copy numbers of the DEFA1/DEFA3  genes 
were detected by using quantitative PCR analysis. To 
evaluate the HNP 1-3 (human neutrophil peptide 1-3 
or α-defensin) levels in the circulation, plasma HNP 
1-3 concentrations were measured by ELISA. The ex-
pression of DEFA1/A3  in peripheral leukocytes of the 
diabetic patients was measured by quantitative RT PCR 
analysis. Three SNPs of the human DEFB1  (human 
defensin β-1) gene: DEFB1  G-20A (rs11362), DEFB1  
C-44G (rs1800972) and DEFB1  G-52A (rs1799946) 
were genotyped by Custom TaqMan® Real Time PCR 
assay.
RESULTS: Significant differences were observed in 
HNP1-3 levels between the healthy subjects and both 
groups of diabetic patients. The mean ± SE was 28.78 ± 
4.2 ng/mL in type 1 diabetes, and 29.82 ± 5.36 ng/mL 
in type 2 diabetes, vs  11.94 ± 2.96 ng/mL in controls; P  
< 0.01 respectively. There was no significant difference 
between patients with type 1 and type 2 diabetes in the 
high plasma concentrations of HNP1-3. The highest con-
centrations of α-defensin were found in diabetic patients 
with nephropathy (49.4 ± 4.8 ng/mL), neuropathy (38.7 
± 4.8 ng/mL) or cardiovascular complications (45.6 ± 
1.45 ng/L). There was no significant difference in the 
cumulative copy numbers of DEFA1/DEFA3  genes be-
tween controls and patients, or between patients with 
the two types of diabetes. Comparisons of HNP 1-3 
plasma level and DEFA1/A3  copy number of the same 
patient did not reveal significant relationship between 
defensin-α levels and the gene copy numbers (r 2 = 
0.01). Similarly, no positive correlation was observed 
between the copy numbers and the mRNA expression 
levels of DEFA1/A3 . Regarding the C-44G polymor-
phism of DEFB1 , the GG “protective” genotype was 
much less frequent (1%-2%) among both groups of 
patients than among controls (9%).
CONCLUSION: Elevated HNP1-3 levels in diabetes are 
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Core tip: There is growing evidence of the role of in-
nate immunity in diabetes To our knowledge our data 
provide the first report on a complex investigation of 
defensin-α and defensin β-1 in type 1 and type 2 dia-
betes. The main conclusion of our manuscript is, that 
the elevated HNP1-3 levels in diabetes are indepen-
dent of the DEFA1/DEFA3  copy numbers, but the GG 
genotype of C-44G SNP in the DEFB1  gene may result 
in a decreased level of defensin β-1 production. Our 
data support the view that both alpha and beta-defen-
sins may have an important role in the pathogenesis of 
diabetes and diabetic complications.
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INTRODUCTION
Defensins are members of  small antimicrobial peptides 
of  the innate immune system[1,2]. However, today these 
peptides are also known as danger signals or ”alarmins” 
playing important roles in inflammation and immunity[3]. 
Mammalian defensins are divided into two major fami-
lies, the α- and β-defensins. Human α-defensins include 
human neutrophil peptide 1-4 (HNP1-4) and intestinal 
human defensins (HD-5 and HD-6) produced by Paneth 
cells. Besides the antimicrobial effects, alpha defensins 
display chemotactic activity and induce proinflammatory 
cytokines[4-6]. HNPs increase the binding of  low density 
lipoprotein (LDL) cholesterol to the endothelial sur-
face suggesting that alpha defensins may modulate the 
development of  atherosclerosis[7]. Neutrophil granulo-
cytes are considered to be the primary cellular origin of  
α-defensins; HNP 1-3 comprise 30%-50% of  the gran-
ule proteins. HNPs can be released into the extracellular 
milieu following granulocyte activation as a consequence 
of  degranulation, leakage, cell death, and lysis during 
inflammation[8]. α-defensins are also involved in the for-
mation of  neutrophil extracellular traps[9].
Human β-defensins make up another family of  anti-
microbial peptides[1,10]. In addition to their antibacterial 
and antiviral effects, the chemoattractive function of  
these defensins has been shown to play a role in immu-
nological reactions that protect the host from various 
pathogens[11]. While the expression of  human defensin 
beta-1 (HBD1) is generally constitutive, the levels of  
human defensin beta-2 (HBD2) are inducible by proin-
flammatory cytokines and bacteria[10,12,13]. Human beta 
defensins are expressed by epithelial cells of  the skin, 
gut, respiratory and urogenital tissues, the pancreas and 
the kidneys. HBD1 is also constitutively expressed by 
leukocytes[14-16].
The level of  defensin expression varies among indi-
viduals, and it has been suggested that this variation is 
due to genetic differences in the genes encoding defen-
sins. Defensin genes have been mapped to 8p22-p23[17]. 
Two types of  genetic polymorphisms have been identi-
fied in genes encoding defensins: copy number polymor-
phisms and single nucleotide poymorphisms (SNPs). 
Human defensin beta-1 (HBD-1) is encoded by the 
gene DEFB1 (OMIM: 602056), in which several SNPs 
(single nucleotide polymorphisms) have been character-
ized. Three frequent SNPs at positions G-20A (rs11362), 
C-44G (rs 1800972) and G-52A (rs1799946) in the 5’
-untranslated region (UTR) of  DEFB1 were described[18]. 
The untranslated variants influence HBD-1 expression 
or function[19].
The cluster of  human alpha-defensin genes on chro-
mosome 8 includes the genes DEFA1 (OMIM: 125220) 
and DEFA3 (OMIM: 604522), which are copy-variables. 
The genes DEFA1 and DEFA3 differ only in a single 
base substitution in the coding sequence, corresponding 
to a single amino acid difference between the peptides 
encoded[20]. HNP 1-3 differs only in a single N-terminal 
acid, and the HNP-2 peptide lacks this residue and 
might be a proteolytic product of  the other two pep-
tides because no separate gene has been identified to 
encode HNP-2[21]. Several copy number polymorphisms 
form the major source of  genetic polymorphism of  
α-defensin genes DEFA1 and DEFA3, encoding human 
neutrophil peptides HNP-1, -2 and 3[20,22]. These genes 
are present in a cluster that is close to but independent 
from the β-defensin cluster on 8p23. The total DEFA1/
DEFA3 copy number has been found to range between 
4 and 11 copies per diploid genome with 5 to 9 copies 
being the most common[22].
To date, little is known about the genetic basis and 
the functions of  α- and β-defensins in diabetes. In-
fections are frequent in diabetic patients because the 
antimicrobial function of  their immune response is 
impaired. It has been reported that mRNA levels of  rat 
β-defensin-1 are significantly low in the kidneys, which 
may explain the high incidence of  urinary tract infec-
tions in diabetes mellitus[23]. The effects of  glucose and 
insulin on the β-defensin expression have recently been 
demonstrated[24], but no connection has been found be-
tween genetic polymorphisms of  the HBD1 gene and 
diabetes in a Brazilian study on diabetic children[25].
Increased levels of  alpha-defensin -1, -2 and -3 have 
recently been reported in patients with type 1 diabe-
tes with nephropathy and in cardiovascular complica-
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tions[26,27]. It is tempting to speculate whether copy num-
ber polymorphisms and the DEFA1/DEFA3 mRNA in 
the granulocytes may influence the levels of  HNP1-3 in 
patients with types 1 and 2 diabetes.
The aim of  our study was to investigate the genetic 
background of  human defensin-α and human defensin 
β-1 production in adult patients with type 1 and type 
2 diabetes, especially with complications. Therefore, 
we carried out an association study between DEFA1/
DEFA3 copy number polymorphism and diabetes, and 
between the promoter polymorphisms of  DEFB1 and 
diabetes. We also measured the plasma levels of  HNP 
1-3 in both types of  diabetes, and the mRNA expression 
of  DEFA1/DEFA3 in leukocytes.
MATERIALS AND METHODS
Patients
257 diabetic patients (122 men and 135 women) were 
enrolled in our study, which included 117 patients with 
type 1 and 140 patients with type 2 diabetes. All patients 
participating in the study were diagnosed according to 
the ADA criteria: Diagnosis and classification of  diabe-
tes mellitus. Diabetes Care 36 (Suppl 1) 2013. S64-S74.
The mean age of  type 1 diabetic patients was 40.6 
years ± 1.51 years, the mean duration of  diabetes was 
17.7 ± 1.12 years, and their mean HbA1c was 8.86% ± 
0.17%. In type 2 diabetic subjects, the mean age was 58.4 
± 1.27 years, the mean duration of  diabetes was 14.5 ± 0.8 
years, and the mean HbA1c was 8.03% ± 0.13%.
Seventy-one subjects in the cohort had diabetic ne-
phropathy (32 with type 1 and 39 with type 2 diabetes) 
defined as an albumin-to-creatinine ratio in a random 
spot collection being higher than 3.4 mg/mmol, or the 
protein content being over 300 mg/d in collected urine. 
Abnormal kidney function was described when the glo-
merular filtration rate (GFR) was lower than 60 mL/min 
per 1.73 m2.
One hunred twenty-one patients suffered from reti-
nopathy (47 with type 1 and 68 with type 2 diabetes). 
This complication was evidenced as the presence of  
background or proliferative retinopathy, macular edema 
or diabetes-related blindness, or the administration of  
retinal photocoagulation therapy. The retinopathy sta-
tus was checked by color stereo-ophthalmography and 
fluorescence angiography. Neuropathy was diagnosed 
in 95 patients (35 with type 1 and 60 with type 2 diabe-
tes). Neuropathy was proven when abnormal peripheral 
sensory functions or altered lower limb tendon reflexes 
as well as impaired cardiovascular reflex tests were de-
tected. 54 diabetic patients (14 with type 1 diabetes and 
40 with type 2 diabetes) had previously been diagnosed 
with macrovascular disease including major coronary 
events, stroke or a transient ischemic attack, peripheral 
artery disease or amputation. A high number of  the pa-
tients (182) had controlled hypertension (50 with type 1 
and 132 with type 2 diabetes).
The control group consisted of  221 age- and gender-
matched healthy blood donors. These control subjects 
were selected from blood donors at the regional Cen-
ter of  Hungarian National Blood Transfusion Service, 
Szeged, Hungary. The exclusion criteria for blood do-
nors were diabetes, nephropathy, hypertension, or isch-
emic heart disease. All cases and controls were of  Hun-
garian ethnic origin and resident in Hungary. Informed 
consent was obtained from all patients and controls, 
and the local Ethics Committee gave prior approval to 
the study. All patients consented to the study and were 
treated according to the Patient Right Protection Act of  
our institutions and according to international guidelines.
Assay of HNP 1-3 concentration
Blood samples containing EDTA were obtained from 
patients and controls. Plasma was isolated after the 
blood was centrifuged at 3000 g for 3 min and stored at 
-80 ℃ for further analysis. The HNP1-3 concentrations 
in plasma were determined by ELISA (Hycult-Biotech 
HK324, Uden, The Netherlands) according to the in-
structions of  the manufacturer.
DNA isolation
Genomic DNA purified from peripheral blood was 
used. Leukocyte DNA was isolated using the High Pure 
PCR Template Preparation Kit according to the instruc-
tions of  the manufacturer (Roche Diagnostic GmbH, 
Mannheim, Germany). DNA concentrations were mea-
sured with a Qubit™ fluorometer (Invitrogen, Carlsbad, 
CA, United States) according to the instructions of  the 
manufacturer. Genomic DNA was stored at -20 ℃ until 
further use.
Determination of DEFA1/DEFA3 gene copy numbers by 
quantitative real-time PCR
Genomic DNA purified from peripheral blood was 
used. Gene copy number determination was carried out 
as previously described by Linzmeier[20] with slight modi-
fications. BIO-RAD CFX 96 instrument (Bio-Rad, Her-
cules, CA, United States) was used for quantitation. The 
reaction volume was 15 μL, containing 3 μL of  DNA, 1 
μmol L-1 each of  the primers, 7.5 μL of  reaction buffer 
(Fermentas Probe/ROX qPCR MasterMix, Fermentas, 
Lithuania) and 0.6 μL EVAGreen (20 × EVAGreen™ 
Biotium Inc., Hayward, CA, United States). Forward 
primer: DEFA1 1 F (5’ TAC CCA CTG CTA ACT CCA 
TAC 3’), reverse primer: DEFA1 1 R (5’ GAA TGC 
CCA GAG TCT TCC C 3’); MPO (myeloperoxidase) 
reference gene primer set MPO 1 F (5’ CCA GCC CAG 
AAT ATC CTT GG 3’), MPO 1 R (5’ GGT GAT GCC 
TGT GTT GTC G 3’). PCR conditions were as follows: 
initial denaturation at 95 ℃ for 10 min followed by 40 
cycles of  denaturation (95 ℃ for 15 s) and extension 
(54 ℃ for 1 min).
Quantification was performed by monitoring the 
emitted fluorescence after each cycle of  PCR reaction 
of  genomic DNA samples in order to identify the exact 
time point at which the log-linear phase could be dis-
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tinguished from the background (crossing point). The 
precise amount of  DNA added to each reaction mix was 
based on optical density. Each DNA sample was ana-
lyzed in triplicate, in 2 independent experiments.
DEFA1/DEFA3 mRNA quantification by RT PCR
We collected further 2 mL of  venous blood in EDTA 
tubes from patients with diabetes and controls. Leuko-
cytes from blood were separated by centrifugation at 
1200 rpm/min for 15 min. By using the reverse tran-
scription polymerase chain reaction (RT-PCR), we exam-
ined the expression of  DEFA1/DEFA3 mRNA in 24 
patients with diabetes (12 cases of  type 1 and 12 cases 
of  type 2 diabetes). Total RNA was extracted with High 
Pure RNA isolation kit (Roche) according the manufac-
turer’s instruction. RNA concentration was determined 
by the A260 value of  the sample. Complementary DNA 
(cDNA) was generated from 1 μg total RNA using the 
High-Capacity cDNA Reverse Transcription Kit (Ap-
plied Biosystems) in a final volume of  20 μL. After 
reverse transcription, amplification was carried out by 
using Light Cycler Fast Start DNA MasterPLUS SYBR 
Green I mix (Roche). Samples were loaded into capil-
lary tubes and placed in the fluorescence thermocycler 
(LightCycler). Initial denaturation at 95 ℃ for 10 min 
was followed by 45 cycles of  95 ℃ for 10 s, annealing at 
58 ℃ for 8 s, and elongation at 72 ℃ for 12 s. DEFA1/
DEFA3 sense, 5’-TCC CAG AAG TGG TTG TTT 
CC-3’; and antisense, 5’-GCA GAA TGC CCA GAG 
TCT TC-3’, and for the housekeeping gene GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) sense, 5′
-AAG GTC GGA GTC AAC GGA TTT-3′; antisense, 
5′-TGG AAG ATG GTG ATG GGA TTT-3′ primers 
were used to amplify specific products from cDNA sam-
ples. At the end of  each run, melting-curve profiles were 
achieved by cooling the sample to 40 ℃ for 15 s, and 
then heating the sample slowly at 0.20 ℃/s up to 95 ℃ 
with continuous measurement of  the fluorescence to 
confirm the amplification of  specific transcripts. Cycle-
to-cycle fluorescence emission readings were monitored 
and analyzed by using LightCycler software (Roche 
Diagnostics GmbH). All quantifications were normal-
ized to the housekeeping GAPDH gene. Relative gene 
expression was determined by using the ∆∆Ct method.
Genotyping of SNPs of human defensin beta-1 (DEFB1)
Genotyping was performed by means of  Custom Taq-
Man® SNP Genotyping Assays (Applied Biosystems, 
CA). Fluorogenic minor groove binder probes were used 
for each case using the dyes 6-carboxyfluorescein (FAM; 
excitation, 494 nm) and VIC (excitation, 538 nm): beta-
defensin-1 polymorphisms DEFB1 G-20A (rs11362) 
Applied Biosystems code c_11636793_20, DEFB1 
C-44G (rs1800972) c_11636794_10 and DEFB1 G-52A 
(rs1799946) c_11636795_20. Thermal cycling was per-
formed on ABI Prism 7000 sequence-detection PCR 
systems. The amplification mix contained the following 
ingredients: 7.5 μL of  TaqMan® universal PCR master 
mix (Applied Biosystems, CA), 0.375 μL of  primer-
probe mix, 6.375 μL of  RNase- and DNase-free water 
(Sigma), and 0.8 μL of  sample DNA, in a total volume 
of  15 μL per single tube reaction. Assay conditions 
were 2 min at 50 ℃, 10 min at 95 ℃, and 40 cycles of  
95 ℃for 15 s and 60 ℃ for 1 min. Each 96-well plate 
contained 90 samples of  an unknown genotype and six 
reactions with reagents but no DNA. DNase-free water 
was used as nontemplate control. Initial and postassay 
analysis was performed by using the Sequence Detection 
System (SDS) version 2.1 software (Applied Biosystems, 
CA) as outlined in the TaqMan Allelic Discrimination 
Guide. Genotypes were determined visually based on 
the dye-component fluorescent emission data depicted 
in the X-Y scatter plot of  the SDS software. Genotypes 
were also determined automatically by the signal pro-
cessing algorithms in the software. Results of  each scor-
ing method were saved in two separate output files for 
later comparison.
Statistical analysis
Comparisons of  plasma concentrations were carried out 
by the Mann-Whitney test and with two-tailed paired 
Student test. The level of  significance of  the genotype 
frequency of  different DEFB1 SNPs was analyzed by 
using the χ 2 test and the Fischer test. Levels P < 0.05 
indicated statistical significance. All statistical calcula-
tions were performed with the Graph Pad Prism 5.0 
statistical program (GraphPad Software, San Diego CA. 
United States). The genotype frequencies for each poly-
morphism of  DEFB1 were tested for deviation from the 
Hardy-Weinberg equilibrium by the χ 2 test with 1 degree 
of  freedom.
RESULTS
Plasma levels of HNP1-3 in patients with type 1 and type 
2 diabetes
In a pilot study, plasma levels of  α-defensin, HNP1-3, 
in 50 patients with type 1 diabetes and in 60 patients 
with type 2 diabetes were determined and compared 
with those of  50 healthy blood donors. There was a high 
individual variation in the plasma levels of  α-defensin, 
but significant differences were observed between the 
healthy subjects and both groups of  diabetic patients. 
The mean value ± SE was 28.78 ± 4.2 ng/mL in patients 
with type 1 diabetes and 29.82 ± 5.36 ng/mL in patients 
with type 2 diabetes vs 11.94 ± 2.96 ng/mL in controls 
(P < 0.01 respectively). The difference between the high 
plasma concentrations of  HNP1-3 in patients with type 
1 or type 2 diabetes was not significant (Figure 1).
Plasma levels of HNP1-3 in diabetic patients with 
complications
After that, we checked whether the generally high level 
of  HNP1-3 in the peripheral blood of  both groups (type 
1 and type 2) of  diabetic patients was connected to dia-
betic complications. Nephropathy was diagnosed in 71 
9131 July 21, 2014|Volume 20|Issue 27|WJG|www.wjgnet.com
Németh BC et al . Defensins in diabetes
patients (32 with type 1 and 39 with type 2 diabetes) and 
neuropathy in 95 ones (35 with type 1 and 60 with type 
2 diabetes). 115 patients suffered from retinopathy (47 
with type 1 and 68 with type 2 diabetes), 54 patients had 
cardiovascular diseases (14 with type 1 diabetes and 40 
with type 2 diabetes), and 182 had hypertension (50 with 
type 1 and 132 with type 2 diabetes). Their data concern-
ing the HNP1-3 levels were compared with those of  the 
67 patients who did not suffer from these complications, 
and with the data of  the 100 healthy subjects (Figure 2). 
The highest HNP 1-3 concentrations were found in the 
diabetic patients with nephropathy (49.4 ± 4.8 ng/mL) 
and with neuropathy (38.7 ± 4.8 ng/mL) or with car-
diovascular complications (45.6 ± 1.4 ng/mL). These 
concentrations were significantly higher than those in 
the diabetic patients without complications (25.4 ± 3.5 
ng/mL). These data are in accordance with previous ob-
servations[26,27] of  high levels of  HNP 1-3 in type 1 dia-
betic patients with cardiovascular diseases. In a relatively 
smaller group of  patients (n = 28) with diabetic foot 
ulcer (20 with type 1 diabetes and 8 with type 2 diabe-
tes), the HNP1-3 plasma levels were 35.9 ± 1.1 ng/mL. 
These high HNP1-3 levels might be the consequence 
of  the degranulation of  recruited neutrophils from the 
skin frequently following infections. Our results suggest 
that in diabetic complications such as nephropathy, neu-
ropathy and cardiovascular diseases, the HNP1-3 level 
in the circulation is elevated independently of  the type 
of  diabetes. All diabetic patients, with or without com-
plications, exhibited significantly higher plasma levels of  
HNP1-3 than the control subjects (Figure 2).
Copy number polymorphism of DEFA1/DEFA3
The cumulative copy numbers of  DEFA1/DEFA3 were 
determined by using quantitative PCR analysis. In the 
control group, 133 DNA samples were used for copy 
number determination and 100 DNA samples of  diabet-
ic patients with type 1 or type 2 diabetes. There was no 
significant difference in copy number between the con-
trols and the patients or between the patients with the 
two types of  diabetes (Figure 3). In the control group, 
DEFA1/DEFA3 copy numbers ranged from 4 to 15 per 
genome with a median number of  10 copies. The me-
dian copy number of  DEFA1/DEFA3 in the patients 
with type 1 diabetes was 10 copies per genome (range 
5 to 16 copies), and that in the patients with type 2 dia-
betes was also 10 (range 5 to 15). Comparing the HNP 
1-3 plasma level and the DEFA1/A3 copy number of  
the same patient, no significant correlation was observed 
between defensin levels and genomic copy numbers (r2 = 
0.01; Figure 4.).
DEFA1/DEFA3 gene expression
The expression of  DEFA1/A3 was measured in the pe-
ripheral leukocytes of  diabetic patients. DEFA1/DEFA3 
mRNA was determined in blood samples from 12 pa-
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Figure 1  Plasma levels of HNP1-3 in patients with type 1 and type 2 dia-
betes (DM1 and DM2) and healthy controls. The line represents the mean 
plasma levels of HNP1-3. Significant differences as determined by Mann-
Whitney test are indicated. NS: Not significant.
Figure 2  Plasma levels of human neutrophil peptides in diabetic patients 
with different complications relative to those without complications, and 
to healthy controls. Mean ± SE are indicated; significant differences between 
groups were determined by unpaired t-test.
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betes and in healthy blood donors. Quantitative box-plot analysis (median, 
minimum, maximum value, 25% and 75% percentiles) of DEFA1/A3 copy num-
bers determined in DNA samples from 133 controls, 100 patients with type 1 
diabetes (DM1), and 100 patients with type 2 diabetes (DM2).
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Table 1  Genotypes of DEFB1 G-20A, DEFB1 G-52A, and 
DEFB1 C-44G polymorphisms in patients with diabetes  n  (%)
tients with type 1 and another 12 with type 2 diabetes, 
and the relative expressions of  DEFA1/DEFA3 were 
compared with the DEFA1/DEFA3 copy numbers of  
the same patients (Figure 5). The data indicated that pe-
ripheral leukocytes had the ability to transcribe DEFA1/
DEFA3 genes (mean ± SE of  relative expression 1.5 ± 
0.28) and to biosynthetize HNP1-3 peptides. However, 
no positive correlation was observed between the copy 
numbers and the expression levels of  the human neutro-
phil peptide 1-3 (Figure 5). The variation in expression 
levels between individuals did not exhibit a positive cor-
relation with the copy number. Similarly, the expression 
of  specific mRNA in the leukocytes for HNP 1-3 did 
not parallel the HNP 1-3 plasma levels (data not shown).
DEFB1 G-20A, DEFB1 G-52A and DEFB1 C-44G 
polymorphisms
The genotypic distributions of  DEFB1 G-20A, and 
DEFB1 G-52A and DEFB1 C-44G polymorphisms are 
presented in Table 1.
The distribution of  the DEFB1 G-20A genotypes 
was in accordance with the Hardy-Weinberg equilibrium 
both in the control population and in the patients (P = 
0.912 and P = 0.795, respectively). There was no sig-
nificant difference in genotype distribution between the 
patients overall and the healthy controls. Similarly, no 
significant differences in genotypes were observed when 
the patients were grouped according to type 1 and type 2 
diabetes.
As concerns the DEFB1 G-52A SNP, distribution 
of  the genotypes was in accordance with the Hardy-
Weinberg equilibrium both in the control population and 
in the patients (P = 0.252 and P = 0.181, respectively). 
We did not detect any significant difference in genotypes 
between the patients and the controls, either in type 1 or 
type 2 diabetes.
The genotypic distribution of  DEFB1 C- 44G poly-
morphism is shown in Table 1.
The distribution of  genotypes was in accordance 
with the Hardy-Weinberg equilibrium among the pa-
tients with diabetes (P = 0.151) and also in the control 
population (P = 0.722). But there was a significant dif-
ference in genotype distribution between the patients 
overall and the healthy controls (χ 2 test, P = 0.002). The 
frequency of  the GG genotype was significantly lower in 
both types of  diabetes (2.5% and 2%, respectively) than 
in the healthy controls (9%) (Fisher test vs control, P = 
0.001, OR = 9.136, 95%CI: 3.512-23.82). Conversely, the 
prevalence of  the DEFB1 CC genotype was 61 % in the 
group of  diabetic patients vs 45% in the controls (Fisher 
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Figure 4  Plasma levels of HNP1-3 in diabetic patients vs copy numbers of 
DEFA1/DEFA3. The DEFA1/A3 copy numbers were determined by quantitative 
PCR analysis and compared to the HNP1-3 plasma level of the same patient (50 
with type 1 and 50 with type 2 diabetes).
Figure 5  Relative mRNA expression levels of DEFA1/DEFA3 in diabetic 
patients vs copy numbers of DEFA1/DEFA3. The DEFA1/A3 copy numbers 
were determined by quantitative PCR analysis and compared to the DEFA1/
DEFA3 mRNA measured by RT-PCR of the same patient (12 with type 1 and 12 
with type 2 diabetes).
DEFB1 G-20A GG GA AA χ 2 test1
   Patients with diabetes   82 (32) 131 (51)   44 (17)   0.568
   n = 257
   Type 1 diabetes   36 (31)   60 (51)   21 (18)   0.775
   n = 117
   Type 2 diabetes   46 (33)   71 (51)   23 (16)   0.573
   n = 140
   Controls   62 (31)   96 (48)   42 (21)
   n = 200
DEFB1 G-52A GG GA AA χ 2 test1
   Patients with diabetes 114 (44) 104 (40)   39 (15)   0.572
   n = 257
   Type 1 diabetes   52 (44)   47 (40)   18 (17)   0.702
   n = 117
   Type 2 diabetes   62 (44)   57 (41)   21 (15)   0.658
   n = 140
   Controls   80 (40)   84 (42)   36 (18)
   n = 200
DEFB1 C-44G CC CG GG χ 2 test1
   Patients with diabetes    156 (61) +   95 (37)    6 (2)2   0.002
   n = 257
   Type 1 diabetes   70 (60)   44 (37)      3 (2.5) 0.01
   n = 117
   Type 2 diabetes   86 (61)   51 (36)   3 (2)   0.003
   n = 140
   Controls   90 (45)   92 (46) 18 (9)
   n = 200
1χ 2 test vs controls; 2Fisher test vs controls, P = 0.001, OR = 9.136, 95%CI: 
3.512-23.82; +: Fisher test vs controls, P = 0.0009, OR = 2.005, 95%CI: 
1.218-2.746.
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test: P = 0.0009, OR = 2.055, 95%CI: 1.248-2.746). 
When the patients were grouped according to the dia-
betic complications, there was a lower frequency of  the 
GG genotype among the patients with nephropathy and 
among those with neuropathy (1.4% and 1%, respec-
tively).
DISCUSSION
HNP1-3 levels in the circulation were measured, and the 
copy number variation of  DEFA1/A3 genes was deter-
mined in diabetic patients. The diabetic patients exhib-
ited overall higher plasma levels of  HNP 1-3 (α-defensin) 
with either type 1 or type 2 form of  the disease than the 
healthy controls. The highest concentrations of  HNPs 
were detected in patients with nephropathic or neuro-
pathic and cardiovascular complications. An essential 
question arises as to why an increased concentration of  
plasma α-defensin (HNP1-3) level is associated with 
type 1 and type 2 diabetes, especially in the event of  dia-
betic complications such as nephropathy, neuropathy or 
cardiovascular problems. The explanation might be that 
the elevation in the plasma HNP1-3 level is the conse-
quence of  the decreased renal degradation of  the pep-
tides in patients with advanced nephropathy[26]. HNP 1-3 
promote the accumulation of  low density lipoprotein in 
the vasculature, inhibit fibrinolytic activity on the surface 
of  vascular cells, and accumulate in the intima of  athero-
sclerotic plaques. Therefore, HNP 1-3 may have clinical 
implications in diabetic patients with hypercholesteremia 
or vascular dysfunction[7,27].
The association of  high levels of  HNP1-3 in patients 
with neuropathy in type 1 and type 2 diabetes is yet to 
be clarified. The next question is whether there is an 
increased gene expression responsible for the elevated 
plasma levels of  α-defensins. Our study revealed that 
there was no correlation between HNP1-3 plasma levels 
and the copy numbers of  DEFA1/A3 genes. The ef-
fect of  copy number variations in DEFA1/DEFA3 on 
the disease or even on the plasma concentrations of  the 
peptides remain unclear. Controversal data have been 
published about the correlation between DEFA1/A3 
copy number and the α-defensin peptide concentration. 
Linzmeier and Ganz[20] have shown that the intracellular 
HNP1-3 levels in human neutrophils are proportional 
to the copy numbers of  the DEFA1 and DEFA3 genes 
Copy numbers of  DEFA1/A3 may be proportional to 
the intracellular levels of  HNP1-3 in neutrophil granulo-
cytes but possibly not to the circulating HNP1-3 levels. 
Additionally, a discrepancy between gene copy number 
and the HNP1-3 protein levels has recently been re-
ported in septic patients[28]. There are several potential 
explanations of  the discrepancy between the gene copy 
number and the plasma levels. HNP1-3 is stored primar-
ily in the granules of  neutrophils and is released into 
the circulation during the activation of  the neutrophils. 
Moreover, it might also be due to different transcription-
al mechanisms modulating these genes or to an increased 
distance between the regulators of  the genes[28,29].
The fact that in our study no significant correlation 
was observed between the genomic copy number varia-
tion of  DEFA1/DEFA3 and the mRNA expression lev-
els (Figure 5) suggests that the degranulation rather than 
the increased gene expression may be responsible for the 
increased plasma HNP 1-3 levels in diabetes.
Similar observations have been published about the 
copy number polymorphism and expression level varia-
tion of  DEFA1 and DEFA3 genes[22]. In that study, the 
combined expression levels of  DEFA1/A3 and the ge-
nomic copy number have not been correlated, suggest-
ing the superimposed influence of  trans-acting factors.
It is noteworthy that there are several examples of  
the absence of  a correlation between copy number poly-
morphisms and the relative transcription level[29].
There are no direct data showing that exaggerated 
degranulation is linked to diabetic complications, or it 
is higher in DM patients than in controls. However, it 
has recently been published that pro-inflammatory con-
ditions during hyperglycemia favor NET - neutrophil 
extracellular traps - formation[30], and HNP 1-3 are also 
involved in the formation of  neutrophil extracellular 
traps[9]. It is noteworthy that diabetes is associated with 
low grade, sub-clinical and chronic inflammation charac-
terized by abnormal cytokine production. Therefore, the 
diabetic microenvironment can induce NET formation, 
which may result in a basic high HNP-1 concentration in 
the circulations.
In order to detect whether increased mRNA expres-
sion is responsible for elevated defensin levels in diabetic 
patients, quantitative RT-PCR reactions were performed. 
Expression of  specific mRNA in the leukocytes was 
observed for HNP 1-3 but not parallel with HNP1-3 
plasma levels. The mRNA values between patients 
and controls were rather equal (mean ± SE of  relative 
expression 1.5 ± 0.28 vs 1.49 ± 0.35, respectively) sug-
gesting that not an increased gene expression may be re-
sponsible for increased plasma levels of  HNP 1-3. Our 
findings were in good correlation with the observations 
of  Fang et al[31], that is, α-defensin genes were constitu-
tively transcribed at low level in mature neutrophils, but 
they were not inducible.
Eosinophils with transcriptionally active α-defensin 
production have recently been detected in the capillary 
blood of  diabetic patients[32]. Eosinophils but not neu-
trophils displayed the augmentation of  transcriptional 
activation of  α-defensin expression. In our study, the 
majority of  the cells in peripheral venous blood were 
neutrophils; therefore, our purified DNA and RNA 
samples were derived mostly from neutrophils.
The present study demonstrated that the distribu-
tions of  the C-44G genotypes were different between 
patients with diabetes and healthy controls, whereas the 
frequency of  the GG genotype was significantly higher 
in the control population. It indicates that the presence 
of  G allele probably leads to strengthened HBD1 anti-
microbial activity, which is less frequent in patients with 
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diabetes. The G allele of  C-44G SNP generates a puta-
tive binding site for nuclear factor κB (NF-κB), and it is 
very likely to induce an overexpression. The proposed 
effect of  this SNP could partially explain why the GG 
genotype was considered to be a protective genotype in 
atopic dermatitis[33] and also in the susceptibility to Can-
dida colonization in diabetic patients[34]. Conversely, in 
these studies, subjects carrying the CC genotype at the 
-44 locus site of  the gene were at a greater risk of  ac-
quiring infection. It has been recently suggested that the 
C allele of  DEFB1 C-44G SNP probably abrogates NF-
κB-dependent DEFB1 upregulation[35].
These data are consistent with our present observa-
tion that the GG phenotype could also be protective 
in diabetes, and vice versa, the higher frequency of  CC 
genotype might be connected with lower expression of  
human defensin β-1. Among the 257 patients with dia-
betes, only 6 (2%) were GG homozygotes, and 61% of  
the patients were CC homozygotes, as compared with 
45% of  CC homozygotes in the control group. Further-
more, the number of  GG homozygotes was even lower 
(1%) among patients with nephropathy and neuropathy. 
These observations draw the attention to the impor-
tance of  DEFB1 polymorphisms in diabetes, especially 
in the cases with nephropathy and neuropathy. Foot 
ulcerations in diabetic patients are often combined with 
infections. None of  the 28 patients with foot ulcer disp-
layed GG genotype of  C- 44G SNP of  DEFB1 gene. A 
high blood glucose level itself  can result in low levels of  
β-defensin[23], and it might be further downregulated in 
humans as a consequence of  C-44G polymorphism. It is 
noteworthy that insulin is an important factor mediating 
hBD-1 expression[24].
Taken together, our study demonstrated elevated 
levels of  α-defensin (HNP1-3) in type 1 and type 2 dia-
betes, which were more pronounced when there were 
diabetic complications. However, there was no correla-
tion between the circulating HNP1-3 levels and the 
DEFA1/DEFA3 copy number. Similarly, no correlation 
was found between the mRNA expression and the copy 
number variation. Further studies are needed to explore 
whether the elevated α-defensin levels of  the plasma in 
diabetes are causally linked to this disease and its compli-
cations, or they are simply the consequences of  the de-
granulation of  neutrophils under pathologic conditions. 
Whatever the mechanism, the elevated HNP1-3 level 
might not be genetically determined or at least inde-
pendent of  the copy number variation of  the DEFA1/
DEFA3 genes. In contrast, the CC genotype of  the 
C-44G SNP of  DEFB1 was more frequent in diabetic 
patients than in healthy controls, which draws the atten-
tion to the genetic background of  a potentially impaired 
function of  hBD1 (human defensin β-1) in diabetes. 
These data support the view that both alpha and beta-
defensins may have important roles in the pathogenesis 
of  diabetes and diabetic complications. Our results 
should be regarded as preliminary results, which should 
be confirmed on a larger series of  patients in a future 
multicenter study.
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Background
There is a growing evidence of the role of innate immunity in diabetes. Defen-
sins are members of small antimicrobial peptides of the innate immune system. 
In addition to their antibacterial and antiviral effects, immunologic functions 
of defensins has been shown to play a role in the homeostasis. To date, little 
is known about the genetic basis and the functions of α- and β-defensins in 
diabetes. The aim of this study was to investigate the genetic background of 
human defensin-α and human defensin β-1 production in adult patients with 
type1 and type 2 diabetes, especially with complications.
Research Frontiers
Neutrophil granulocytes are considered to be the primary cellular origin of 
α-defensins; HNP 1-3. HNPs can be released into the extracellular milieu fol-
lowing granulocyte activation as a consequence of degranulation, leakage, cell 
death, and lysis during inflammation. Human beta defensins are expressed 
mainly by epithelial cells of the skin, gut, respiratory and urogenital tissues, 
the pancreas and the kidneys. The level of defensin expression varies among 
individuals, and it has been suggested that this variation is due to genetic differ-
ences in the genes encoding defensins.
Innovations and breakthroughs
These data provide the first report about a complex investigation of defensin-
alpha and defensin β-1 in type 1 and type 2 diabetes. Increased levels of 
alpha-defensin -1, -2 and -3 have recently been reported in patients with type 1 
diabetes with nephropathy and in cardiovascular complication. In this study not 
only HNP1-3 levels in the circulation were measured, but also the copy number 
variation of DEFA1/A3 genes was determined in diabetic patients, together with 
the expression of DEFA1/A3 in peripheral leukocytes. Several SNPs (single 
nucleotide polymorphisms) have been characterized of human DEFB1 (hu-
man defensin β-1) gene in previous studies. In this complex study the authors 
demonstrated that elevated HNP1-3 levels in diabetes are independent of 
DEFA1/DEFA3 copy numbers, but the GG genotype of C-44G SNP in DEFB1 
gene may result in decreased β1-defensin production.
Applications
The data support the view, that both alpha and beta-defensins may have an 
important role in the pathogenesis of diabetes and diabetic complications. The 
results may contribute to a better understanding of the roles of defensins in 
the pathomechanism of diabetes and may represent a future possibility toward 
broadening of the prognostic laboratory markers.
Terminology
HNP 1-3 are Human Neutrophil Peptides, members of the human α-defensin 
family. Human defensin β-1 (HBD1) is the member of another family of antimi-
crobial peptides. Two types of genetic polymorphisms have been identified in 
genes encoding defensins: copy number polymorphisms and single nucleotide 
poymorphisms (SNPs). Several copy number polymorphisms form the major 
source of genetic polymorphism of α-defensin genes DEFA1 and DEFA3, en-
coding human neutrophil peptides Human defensin beta-1 (HBD-1) is encoded 
by the gene DEFB1. Three frequent SNPs at positions G-20A (rs11362), C-44G 
(rs 1800972) and G-52A (rs1799946) in the 5’-untranslated region (UTR) of 
DEFB1 were described. The untranslated variants influence HBD-1 expression 
or function.
Peer review
The current manuscript addresses the role of defensins in patients with type 
1 and type 2 diabete. The authors, in addition to the protein levels, correlate 
absolute mRNA expression to the diabetic patients. The authors explain the 
biological role/relevance of the defensine increase.
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